Drug Versus Radioactive Treatment of Graves' Disease - Metabolic Outcomes - oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Abstracts & Posters

Drug Versus Radioactive Treatment of Graves’ Disease – Metabolic Outcomes

key information

source: Endocrine Society

year: 2016

authors: Elena Izkhakov, Mariana Yaron, Karen Michele Tordjman, Yona Greenman, Naftali Stern

summary/abstract:

Background:
Weight gain is a common complaint in patients treated for Graves’ disease.We compared rates of weight gain, hypertension, glucose intolerance, and disturbance in lipid profile, following radioactive iodine (RAI) and antithyroid drug treatment in Graves’ patients.

Methods:
This is a cross-sectional study of patients with Graves’ disease treated at one institute between the years 2003-2010.Patients underwent physical examinations, which included height, weight and blood pressure (BMI calculated); 24 hour ambulatory blood pressure monitoring and blood measurements of fasting glucose, thyroid function and lipid profile. Additionally, we compared current to self reported past data regarding weight and BMI.

Results:
Of 113 patients, 68 (53 women) received RAI therapy and 45 (36 women) were treated with thioamides. Mean ages were 53 (95% CI: 50-56) and 48 (95% CI: 44-52) years, respectively, and median duration of disease: 5 (IQR: 4-6) and 6 (IQR: 3-8) years. After adjustment for sex, age and disease duration, body weight increased by a mean of 9.9% for RAI treated patients and 4.6% for medically treated subjects (P<0.025). Newly diagnosed dyslipidemia (detected after the diagnosis/treatment of Graves’ disease) was more common in RAI-treated than in medically treated patients (37.7% vs 17.1%; P<0.028). Further, RAI treated patients had a higher number of components of the metabolic syndrome compared to the drug treated patients (2.0 vs 1.4; p<0.018)

Conclusions:
The results of this study are consistent with some previously reported data concerning the outcome of the main two modalities of the treatment of hyperthyroidism. The key findings in our study are that compared to medically treated patients with Graves’ disease, RAI-treated subjects with the same disease experienced a significantly larger increase of the body weight and had a higher rate of new-onset dyslipidemia with significantly higher number of components of the metabolic syndrome.

organization: Tel Aviv University, Israel

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

© 2022 rareLife solutions Inc.